Arrow-right Camera

The Spokesman-Review Newspaper
Sunday, December 09, 2018  Spokane, Washington  Est. May 19, 1883
38˚Clear Day

News >  Business

Drugmaker to sell cheaper generic rival to EpiPen injectors

UPDATED: Thu., Dec. 6, 2018, 8:29 p.m.

This image provided by Sandoz Inc. shows a portion of the new epinephrine injector by Sandoz Inc. (Associated Press)
This image provided by Sandoz Inc. shows a portion of the new epinephrine injector by Sandoz Inc. (Associated Press)

TRENTON, N.J. – Generic drugmaker Sandoz announced plans Thursday to start selling a slightly cheaper version of the EpiPen in the U.S. early next year.

The penlike injectors are used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.

Sandoz will sell a pair of injectors, under the name Symjepi, for $250 without insurance. Two other generics on the market in the U.S. cost $300 a pair, including one from EpiPen seller Mylan. The company started selling its own generic after it was blasted for repeated increases that pushed up its list price from $94 to $608 for a pair of brand-name EpiPens.

What people pay varies, though, depending on insurance, discounts and the pharmacy.

Mylan’s injectors are made by a subsidiary of Pfizer, which is upgrading factories to fix quality problems. That resulted in production slowdowns. Pfizer said Thursday it’s shipping some injectors and expects to ship more in the coming months.

The shortages triggered temporary shortages of other injectors, including Auvi-Q. As a result, U.S. regulators let some manufacturers extend expiration dates.

Sandox, part of Novartis AG., will sell adult injectors made by Adamis Pharmaceuticals Corp. A children’s version will follow.

Israel’s Teva Pharmaceutical Industries began selling limited quantities of its new generic EpiPen in the U.S. past week.


Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter

There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com

You have been successfully subscribed!